Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Jump to

    • Interview: How Cipla plans to bounce back after a weak Q2

    • Revenue is a challenge for us; little concerned about revenue growth: Cipla

    • See limited competition for Pulmicort; expect 3-4 more approvals by FY18-end: Cipla

    • Will continue to pursue inorganic growth in India & US: Torrent Pharma

    • New draft pharma policy will reduce risks like generalisation of mkt: JM Financial

    • Cipla to remain unfazed by Trump's protectionist policy

    • Looking for bigger partnership with Cipla: Serum Institute

    • Indian pharma cos need to step-up safeguards at plants: Handa

    • 20% of Cipla FY17 revenues to come from US: Chirag Talati

    • Cipla completes acquisition of US cos InvaGen and Exelan

    • Sub-license for Hepatitis C drug beneficial for patients: Cipla

    • Cipla to pay for InvaGen, Exelan mostly through own funds

    • Aiming to achieve 70-80% organic growth: Cipla

    • Consumer health mkt growing at high double digit: Cipla

    • See Rs 400cr increase in top line over next few yrs: Hetero

    • What a potential Cipla-Serum merger could mean

    • Serum Institute in 'initial talks' to explore Cipla merger

    • Sun's margins may reduce to 30-32% post merger: Surajit Pal

    • Discussing partnerships, have done in-licensing deals:Cipla

    • Aiming growth of USD 3-4 bn by 2020: Cipla

    • Indian mkt needs hostile takeovers: Grant Thornton

    • Cipla mgmt rejig: Time to act as godfather says YK Hamied

      Dr.YK Hamied, CMD, Cipla will retire with effect on March 31.Talking to CNBC-TV18 about his retirement plans, YK Hamied, CMD, Cipla says, “We now have built up a very strong senior management team and time has come to let the youngsters‘ takeover.

    • Cipla eyes South Africa with plans for Cipla Medpro stake

      S Radhakrishnan, ED, Cipla explains to CNBC-TV18 that the company is in discussions to acquire a 51 percent stake in Cipla Medpro, South Africa for a consideration of USD 220 million. The acquisition also offers a stake in Cipla Medpro business in South Africa.

    • Cipla launches anti-malarial drug in India

      In an interview to CNBC-TV18, YK Hamied, chairman and managing director of Cipla says, the company is launching an anti-malarial drug in India. "Today, being the World Malaria day, we are launching a new combination drug along with our partners who are based in Geneva called DNDI," he asserts.

    • Cipla aims for 8-10% revenues this yr; Eyes overseas growth

      YK Hamied, the CMD of Cipla is optimistic the pharma major will post a topline growth of 8-10% this fiscal.In an interview to CNBC-TV18, he says he is looking at the company's bottomline increasing by Rs 1,000 crore in FY13.

    Advisory Alert:

    It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347